REMS Document Initial Approval[removed]NDA[removed] Iclusig® (ponatinib) tablets

First Page		Document Content
Ponatinib Chronic myelogenous leukemia Rems Alkynes Organofluorides Piperazines		REMS Document Initial Approval[removed]NDA[removed] Iclusig® (ponatinib) tablets Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 1,35 MB Share Document on Facebook